Lessons Learned In Immuno-Oncology From Former Roche Exec Dan Chen
In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.
You may also be interested in...
Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.